Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer

BackgroundThe rising incidence of breast cancer and its heterogeneity necessitate precise tools for predicting patient prognosis and tailoring personalized treatments. Epigenetic changes play a critical role in breast cancer progression and therapy responses, providing a foundation for prognostic mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao Guo, Chuanbo Feng, Jiaying Xing, Yuyan Cao, Tengda Liu, Wenchuang Yang, Runhong Mu, Tao Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510829/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841540147593609216
author Xiao Guo
Chuanbo Feng
Jiaying Xing
Yuyan Cao
Tengda Liu
Wenchuang Yang
Runhong Mu
Tao Wang
author_facet Xiao Guo
Chuanbo Feng
Jiaying Xing
Yuyan Cao
Tengda Liu
Wenchuang Yang
Runhong Mu
Tao Wang
author_sort Xiao Guo
collection DOAJ
description BackgroundThe rising incidence of breast cancer and its heterogeneity necessitate precise tools for predicting patient prognosis and tailoring personalized treatments. Epigenetic changes play a critical role in breast cancer progression and therapy responses, providing a foundation for prognostic model development.MethodsWe developed the Machine Learning-derived Epigenetic Model (MLEM) to identify prognostic epigenetic gene patterns in breast cancer. Using multi-cohort transcriptomic datasets, MLEM was constructed with rigorous machine learning techniques and validated across independent datasets. The model’s performance was further corroborated through immunohistochemical validation on clinical samples.ResultsMLEM effectively stratified breast cancer patients into high- and low-risk groups. Low-MLEM patients exhibited improved prognosis, characterized by enhanced immune cell infiltration and higher responsiveness to immunotherapy. High-MLEM patients showed poorer prognosis but were more responsive to chemotherapy, with vincristine identified as a promising therapeutic option. The model demonstrated robust performance across independent validation datasets.ConclusionMLEM is a powerful prognostic tool for predicting breast cancer outcomes and tailoring personalized treatments. By integrating epigenetic insights with machine learning, this model has the potential to improve clinical decision-making and optimize therapeutic strategies for breast cancer patients.
format Article
id doaj-art-c1c8213d431b45538d453a619eb70dfc
institution Kabale University
issn 1664-3224
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-c1c8213d431b45538d453a619eb70dfc2025-01-14T06:10:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15108291510829Epigenetic profiling for prognostic stratification and personalized therapy in breast cancerXiao Guo0Chuanbo Feng1Jiaying Xing2Yuyan Cao3Tengda Liu4Wenchuang Yang5Runhong Mu6Tao Wang7School of Pharmacy, Beihua University, Jilin, ChinaSchool of Pharmacy, Beihua University, Jilin, ChinaSchool of Pharmacy, Beihua University, Jilin, ChinaSchool of Pharmacy, Beihua University, Jilin, ChinaSchool of Pharmacy, Beihua University, Jilin, ChinaSchool of Pharmacy, Beihua University, Jilin, ChinaSchool of Basic Medical Sciences, Beihua University, Jilin, ChinaResearch Laboratory Center, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, ChinaBackgroundThe rising incidence of breast cancer and its heterogeneity necessitate precise tools for predicting patient prognosis and tailoring personalized treatments. Epigenetic changes play a critical role in breast cancer progression and therapy responses, providing a foundation for prognostic model development.MethodsWe developed the Machine Learning-derived Epigenetic Model (MLEM) to identify prognostic epigenetic gene patterns in breast cancer. Using multi-cohort transcriptomic datasets, MLEM was constructed with rigorous machine learning techniques and validated across independent datasets. The model’s performance was further corroborated through immunohistochemical validation on clinical samples.ResultsMLEM effectively stratified breast cancer patients into high- and low-risk groups. Low-MLEM patients exhibited improved prognosis, characterized by enhanced immune cell infiltration and higher responsiveness to immunotherapy. High-MLEM patients showed poorer prognosis but were more responsive to chemotherapy, with vincristine identified as a promising therapeutic option. The model demonstrated robust performance across independent validation datasets.ConclusionMLEM is a powerful prognostic tool for predicting breast cancer outcomes and tailoring personalized treatments. By integrating epigenetic insights with machine learning, this model has the potential to improve clinical decision-making and optimize therapeutic strategies for breast cancer patients.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510829/fullbreast cancerepigeneticsmachine learningpersonalized therapyvincristine
spellingShingle Xiao Guo
Chuanbo Feng
Jiaying Xing
Yuyan Cao
Tengda Liu
Wenchuang Yang
Runhong Mu
Tao Wang
Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
Frontiers in Immunology
breast cancer
epigenetics
machine learning
personalized therapy
vincristine
title Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
title_full Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
title_fullStr Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
title_full_unstemmed Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
title_short Epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
title_sort epigenetic profiling for prognostic stratification and personalized therapy in breast cancer
topic breast cancer
epigenetics
machine learning
personalized therapy
vincristine
url https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510829/full
work_keys_str_mv AT xiaoguo epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT chuanbofeng epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT jiayingxing epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT yuyancao epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT tengdaliu epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT wenchuangyang epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT runhongmu epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer
AT taowang epigeneticprofilingforprognosticstratificationandpersonalizedtherapyinbreastcancer